Company intelligence / Profile preview

Ilasis Laser

Ownership: Private
Development stage: Commercial

Overview

The Rx femtosecond laser system has been used to treat over 200 patients as of September 2023. It offers a reproducible and predictable method for performing capsulotomies during cataract surgery, with a focus on accessibility and ease of use at lower cost compared to traditional systems. Clinical results emphasize safety, efficiency, and a faster learning curve for surgeons. The company recently raised €4.4 million to support commercial expansion in Europe and regulatory efforts in the United States.

Therapeutic areas: Ophthalmology
Modalities: Devicespecifically Femtosecond laser surgical instrument
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Ilasis Laser.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ilasis Laser.

Explore the full profile